Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Standard Biotools (LAB) Other Accumulated Expenses (2022 - 2025)

Standard Biotools (LAB) has disclosed Other Accumulated Expenses for 4 consecutive years, with $2.5 million as the latest value for Q3 2025.

  • On a quarterly basis, Other Accumulated Expenses changed N/A to $2.5 million in Q3 2025 year-over-year; TTM through Sep 2025 was $2.5 million, a N/A change, with the full-year FY2024 number at $4.7 million, up 15.5% from a year prior.
  • Other Accumulated Expenses was $2.5 million for Q3 2025 at Standard Biotools, down from $4.6 million in the prior quarter.
  • In the past five years, Other Accumulated Expenses ranged from a high of $4.7 million in Q4 2024 to a low of $913000.0 in Q4 2022.
  • A 4-year average of $3.4 million and a median of $4.0 million in 2023 define the central range for Other Accumulated Expenses.
  • Peak YoY movement for Other Accumulated Expenses: surged 341.73% in 2023, then grew 15.5% in 2024.
  • Standard Biotools' Other Accumulated Expenses stood at $913000.0 in 2022, then soared by 341.73% to $4.0 million in 2023, then increased by 15.5% to $4.7 million in 2024, then tumbled by 46.39% to $2.5 million in 2025.
  • Per Business Quant, the three most recent readings for LAB's Other Accumulated Expenses are $2.5 million (Q3 2025), $4.6 million (Q1 2025), and $4.7 million (Q4 2024).